ML351

Research use only, not for human use.

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM).

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM).

——

Animal Model:Nine-week-old male C57BL/6J miceDosage:0 mg/kg; 24 mg/kg; 48 mg/kg;Administration:Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ Result: Protected against diabetes development in an STZ β-cell injury model that mimics the inflammation seen in T1D.Animal Model:Female NOD mice develop spontaneous autoimmune diabetes between 12 and 24 weeks of age Dosage:0 mg/kg; 24 mg/kg; 48 mg/kg;Administration:Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ Result:Protected Against Early Glycemic Deterioration in NOD Mice.

——

Immunology/Inflammation

Lipoxygenase

15 LOX

——

——

847163-28-4

249.27

C15H11N3O

>98% (HPLC)

DMSO:10 mM

CNC1=C(N=C(O1)C2=CC=CC3=CC=CC=C32)C#N

——

(-20℃)

With Ice Pack

≥ 2 years